• Profile
Close

Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study

Diabetes Therapy Jan 07, 2018

Hollander P, et al. - The safety and efficacy of ertugliflozin (an oral sodium-glucose cotransporter 2 inhibitor) vs glimepiride were assessed in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin. In reducing HbA1c, ertugliflozin 15 mg was non-inferior to glimepiride when added to metformin in patients with T2DM. Ertugliflozin had an acceptable safety profile. Compared to glimepiride, ertugliflozin resulted in less hypoglycemia and more genital mycotic infections (GMIs).
Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay